Has the Bubble Burst for Viking Therapeutics Stock?

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have been hoping that another, larger healthcare company would acquire it for its promising GLP-1 treatment, VK2735 -- but that doesn't appear to be happening.And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's rapidly declining valuation be a sign that the bubble has burst for it, given its inflated price, or is the healthcare stock due for a big rally this year?Shares of Viking soared early last year after the company posted encouraging data for VK2735 from a phase 2 clinical trial, which showed that the injectable drug helped people lose close to 15% of their body weight after a period of just 13 weeks. The company is also working on an oral version, which is not as far along.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool